CRDL Cardiol Therapeutics Earnings per share growth rate in current year

Corporate emblem and logo of Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL) is developing an innovative cannabidiol-based therapy for pericarditis. However, global instability and sanctions are complicating overseas testing and patent protection, which is reflected in the annual earnings per share growth profile on the GURU.Markets terminal, where -8.60 records a new level. Current revenues remain unpredictable, as the company's financial success relies entirely on the results of clinical trials.

CRDL: Cardiol Net earnings per share growth this year 07/04/2022 - 11/16/2026

Financial and market metric breakdowns for Cardiol (CRDL)

- current quotes and average value forecast:
Fundamental valuation:CRDL cardiolrx.com
Flagship merchandise of Cardiol Therapeutics Inc

For the cardiology biotech Cardiol Therapeutics (CRDL), earnings per share dynamics serve as a key indicator of operational efficiency. This metric calculates the percentage change in annual net income, reflecting the growth rate of returns per ordinary share. By analyzing the percentage deviation of EPS from the previous year, an investor can discern the actual acceleration of the business. For a company with no debt, this indicator confirms the quality of capital management. Steady growth of this metric verifies the success of clinical trials.